A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

January 9, 2020

Study Completion Date

January 9, 2020

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Seladelpar

Capsule(s) administered orally once daily

DRUG

Placebo to match Seladelpar

Capsule(s) administered orally once daily

Trial Locations (10)

10016

New York University, New York

23226

Bon Secours Liver Institute of Richmond, Richmond

23602

Liver Institute of Virginia, Newport News

30309

Piedmont Atlanta Hospital, Atlanta

33136

Schiff Center for Liver Diseases/University of Miami, Miami

48377

Henry Ford Health System, Novi

80045

University of Colorado Denver and Hospital, Aurora

94109

Sutter Pacific Medical Foundation - California Pacific Medical Center, San Francisco

M5G 2C4

Toronto Centre for Liver Disease-Toronto General Hospital, Toronto

41-400

ID Clinic, Mysłowice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY